Multidisciplinary Task Force: Increasing Early Intervention and Optimizing Management in Psoriatic Arthritis
Webcast
1.25 AMA PRA Category 1 Credits™ ...Faculty
OVERVIEW
Multidisciplinary Task Force: Increasing Early Intervention and Optimizing Management in Psoriatic Arthritis is organized by i3 Health.
DATES AVAILABLE
March 5, 2025 - March 4, 2026
STATEMENT OF NEED
Psoriatic arthritis is a chronic inflammatory disorder that affects approximately 20% of patients with psoriasis. Symptoms, which include joint pain, stiffness, swelling, tendon and ligament tenderness, silvery or gray scaly patches, nail discoloration, and fatigue, usually manifest in flares and greatly impact patients’ quality of life (Kimak et al, 2023; Cleveland Clinic, 2023). Many patients are not diagnosed with psoriatic arthritis until later stages when lesions are irreversible. Screening for risk factors and early symptoms, in addition to incorporating novel imaging modalities and biomarkers, is crucial to making an early diagnosis and administering treatment that can prevent or delay the disease (Kimak et al, 2023). With numerous novel therapies in development, it is critical for members of the multidisciplinary team to remain up to date on emerging data in order to tailor treatment selection and sequencing. This Multidisciplinary Task Force explores strategies for increasing early intervention and optimizing management of psoriatic arthritis. It features perspectives from Christopher Ritchlin, MD, MPH, Professor and Chief of the Division of Allergy, Immunology and Rheumatology at the University of Rochester Medical Center; Jennifer Soung, MD, Director of Clinical Research at Southern California Dermatology and Clinical Faculty at Harbor University of California, Los Angeles; Archie Franklin, MBA, Patient Advocate and Volunteer for the National Psoriasis Foundation; Saba Mohiuddin, PharmD, BCACP, Clinical Pharmacist at KabaFusion; and Melodie S. Young, MSN, A/GNP-C, Nurse Practitioner at Mindful Dermatology and Modern Research Associates.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Utilize knowledge of defining features, screening tools, and biomarkers to provide timely and accurate diagnosis of psoriatic arthritis
- Evaluate the safety and efficacy of novel psoriatic arthritis therapies
- Appraise strategies for tailoring treatment selection and sequencing to individual patients with psoriatic arthritis
- Assess methods to improve supportive care for patients with psoriatic arthritis
ACCREDITATION & CREDITS
JOINTLY ACCREDITED PROVIDER
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS
i3 Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 3/4/26. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
A maximum of 1.25 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 1.25 ANCC contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.25 ANCC contact hours.
Continuing Pharmacy Education
i3 Health has approved this knowledge-based activity for 1.25 ACPE CE hours. The Universal Activity Number for this activity is JA0008128-0000-25-016-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.
TARGET AUDIENCE
PhysicianNursingPharmacistPhysician AssistantDermatologistsHealthcare ProfessionalsNursesPrimary Care PhysiciansNurse PractitionersRheumatologistsSPECIALITIES
RheumatologyRELATED ONLINE COURSES
Quick Links